Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate is AlloNK, an off-the-shelf NK cell therapy for patients with conditions such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company is also developing AB-201, an allogeneic CAR-NK candidate targeting solid tumors including breast, gastric, esophageal, and bladder cancers, as well as AB-205 for hematological malignancies.

Revenue increased from $2.0M in FY2021 to $4.9M in FY2022 and $33.5M in FY2023, before falling 99.3% to $251,000 in FY2024. This represented a 3-year revenue CAGR of -50.0%. In FY2024, the operating margin stood at -26805.6% and net income was -$58.5M, yielding an EPS of -$25.02. Annual R&D expense totaled $50.3M in both FY2023 and FY2024. For the trailing twelve months ended June 30, 2026, revenue was $0, with quarterly revenue growth of -100.0% year-over-year. TTM EPS was -$3.23, while return on equity was -36.6% and return on assets was -22.3%.

As of June 30, 2026, Artiva held $349.4M in cash and short-term investments against total debt of $9.8M, resulting in net cash of $339.5M. Shareholders' equity was $347.5M out of $368.6M in total assets. The company reported a current ratio of 24.16 and a debt-to-equity ratio of 0.03. Cash flow from operations was -$55.0M in FY2024, and free cash flow was -$55.7M. Capital expenditures stood at $2.6M in FY2025.

At a last close of $5.85 on October 16, 2026, Artiva had a market capitalization of $286.0M and an enterprise value of $37.4M. Its price-to-sales ratio was 8.1x and EV-to-revenue was 7.5x, trading at a premium to the median price-to-sales ratio of 4.1x for US-listed Healthcare peers. Price-to-book stood at 1.1x. Over the past year, the stock gained 111.2%, outpacing the S&P 500 (SPY) return of 16.8%. Year-to-date return was 36.4%, though the price remained 26.7% below its 200-day average.

Wall Street coverage includes 5 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell ratings. The mean price target is $35.80, representing an increase of 512.0% above the last close of $5.85. For the fiscal year ending December 31, 2026, consensus estimates project EPS of -$2.51 and revenue of $0. For the following fiscal year, 5 analysts project EPS of -$2.61 and revenue of $0. Artiva beat EPS estimates in 1 of the last 4 quarters, with the next earnings date scheduled for November 11, 2026.

This page is an AI-written research summary of Artiva Biotherapeutics, Inc. (ARTV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ARTV income statement, ARTV balance sheet, ARTV key metrics, ARTV analyst forecast, ARTV chart. See the ARTV stock overview for the latest quote and news.